Last reviewed · How we verify
TC-D101 CAR-T
At a glance
| Generic name | TC-D101 CAR-T |
|---|---|
| Also known as | Fludarabine, Cyclophosphamide |
| Sponsor | TCRCure Biopharma Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TC-D101 CAR-T CI brief — competitive landscape report
- TC-D101 CAR-T updates RSS · CI watch RSS
- TCRCure Biopharma Ltd. portfolio CI